Comparison of loracarbef (LY163892) versus amoxicillin in the treatment of bronchopneumonia and lobar pneumonia

Infection

Volumn 20, Issue 3, 1992, Pages 176-182

  Muller O ^a   Wettich, K ^b  

^a Lilly Deutschland GmbH ^*

^b LILLY DEUTSCHLAND GMBH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; BETA LACTAM ANTIBIOTIC; LORACARBEF;

ADOLESCENT; ADULT; AGED; ARTICLE; BRONCHOPNEUMONIA; CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; FEMALE; HAEMOPHILUS INFLUENZAE; HEADACHE; HUMAN; HYPERVENTILATION; LOBAR PNEUMONIA; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; NAUSEA; ORAL DRUG ADMINISTRATION; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; STREPTOCOCCUS PNEUMONIAE; VOMITING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMOXICILLIN; BRONCHOPNEUMONIA; CEPHALOSPORINS; COMPARATIVE STUDY; DOUBLE-BLIND METHOD; DRUG RESISTANCE, MICROBIAL; FEMALE; HUMAN; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGE; PNEUMONIA, PNEUMOCOCCAL; RECURRENCE;

EID: 0026638661     PISSN: 03008126     EISSN: 14390973     Source Type: Journal    
DOI: 10.1007/BF01704619     Document Type: Article

References (30)

1. Long-term epidemiology of infections with Mycoplasma pneumoniae
2. Mixed Streptococcus pneumoniae and gram-negative bacillary pneumonia in the elderly
3. Incidence, etiology and outcome of nosocomial pneumonia in mechanically ventilated patients
4. Severe community acquired pneumonia. Epidemiology and prognostic factors
5. Aetiology, outcome and prognostic factors in community-acquired pneumonia requiring hospitalization
6. Prognosis in community-acquired pneumonia requiring treatment in hospital. Importance of predisposing and complicating factors, and of diagnostic procedures
7. Therapeutics of community-acquired pneumonias
8. Aetiology of community-acquired pneumonia
9. Community-acquired pneumonia in adults and British Hospitals in 1982–1983: a survey of aetiology, mortality, prognostic factors and outcome
10. Effect of tobacco and nicotine on growth of Haemophilus influenzae in vitro
11. Acute pneumonia
12. comparative reactivity of 1-carba-1-dethiacephalosporins with cephalosporins
13. 3- Sulfonyl-1-carba-1-dethiacephems
14. In vitro activity of cefprozil (BMY 28100) and loracarbef (LY163892) against pathogens obtained from middle ear fluid
15. In vitro activity and β-lactamase stability of LY163892
16. Comparative in vitro activity of a new oral carbacephem LY 163892
17. Antimicrobial activity of LY163892, an orally administered 1-carbacephem
18. Critical assessment of the newer non-quinolone oral antimicrobial agents
19. Antimicrobial resistance among respiratory isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae in the United States
20. In vitro activities of LY163892, cefaclor and cefuroxime
21. Comparative in vitro activities of several new fluoroquinolones and beta-lactam antimicrobial agents against community isolates of Streptococcus pneumoniae
22. In vitro activity and beta-lactamase stability of LY163892
23. In vitro and in vivo antibacterial activity of KT3777, a new orally active carbacephem
24. In vitro susceptibilities of common pediatric pathogens to LY163892
25. C(3)-cysclopropyl cephems and carbacephems
26. In vitro activity of LY163892 against pathogens isolated from pediatric patients
27. Community-acquired bacterial pneumonia in the elderly
28. Influence of storage and susceptibility test conditions on stability and activity of LY163892 and four other cephalosporins
29. The effect of prescribed daily dose frequency on patient medication compliance
30. Beta-lactamase hydrolysis and inhibition studies of the new 1-carbacephem LY163892